Novartis (France)

925 papers and 27.0k indexed citations i.

About

In recent decades, authors affiliated with Novartis (France) have published 925 papers, which have received a total of 27.0k indexed citations. Scholars at this organization have produced 207 papers in Pulmonary and Respiratory Medicine, 188 papers in Oncology and 150 papers in Molecular Biology on the topics of Chronic Myeloid Leukemia Treatments (68 papers), Chronic Lymphocytic Leukemia Research (63 papers) and Advanced Breast Cancer Therapies (58 papers). Their work is cited by papers focused on Oncology (7.0k citations), Molecular Biology (5.6k citations) and Pulmonary and Respiratory Medicine (5.4k citations). Authors at Novartis (France) collaborate with scholars in France, United States and Switzerland and have published in prestigious journals including New England Journal of Medicine, The Lancet and Journal of Clinical Investigation. Some of Novartis (France)'s most productive authors include S. Dejager, Éric Bruckert, Bernard Bégaud, Robert E. Coleman, Anja Schweizer, Gilles Hayem, Vincent Gros, Mathiéu Molimard, John J. Seaman and James E. Foley.

In The Last Decade

Fields of papers published by authors at Novartis (France)

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers affiliated with Novartis (France) at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Novartis (France) at the time of their publication.

Countries citing scholars working at Novartis (France)

Since Specialization
Citations

This map shows the geographic impact of research produced by authors working at Novartis (France). It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Novartis (France) with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Novartis (France) more than expected).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar’s output or impact.

Explore institutions with similar magnitude of impact

Rankless by CCL
2025